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Abstract
Background: C-X-C chemokine receptor type 4 (CXCR4) may be involved in the development of pulmonary arterial
hypertension (PAH). CXCR4 inhibitor AMD3100 was described to have a positive effect on the prevention of
pulmonary arterial muscularization in PAH models. Silibinin is a traditional medicine that has an antagonistic effect
on CXCR4. We investigated the effect of silibinin using rat models of PAH.
Methods: PAH was induced by a single subcutaneous injection of monocrotaline. The rats were maintained in a
chronic hypoxic condition (10% O2) with or without silibinin. To evaluate the efficacy of silibinin on PAH, right
ventricular systolic pressure (RVSP), Fulton index (weight ratio of right ventricle to the left ventricle and septum),
percent medial wall thickness (% MT), and vascular occlusion score (VOS) were measured and calculated.
Immunohistochemical analysis was performed targeting CXCR4 and c-Kit. Reverse transcription-quantitative polymerase
chain reaction was performed for the stem cell markers CXCR4, stromal cell derived factor-1 (SDF-1), c-Kit, and stem cell
factor (SCF), and the inflammatory markers monocyte chemoattractant protein 1 (MCP1), interleukin-6 (IL-6), and tumor
necrosis factor alpha (TNFα). Statistical analyses were performed using t-test and one-way analysis of variance with
Bonferroni’s post hoc test.
Results: Silibinin treatment for 1 week reduced RVSP and Fulton index. Treatment for 2 weeks reduced RVSP, Fulton
index, % MT, and VOS, as well as downregulating the expression of CXCR4, SDF-1, and TNFα in pulmonary arteries. In
contrast, treatment for 3 weeks failed to ameliorate PAH. The time-course study demonstrated that RVSP, Fulton index,
% MT, and VOS gradually increased over time, with a decrease in the expression of CXCR4 and TNFα occurring after 2
weeks of PAH development. After 3 weeks, SDF-1, c-Kit, and SCF began to decrease and, after 5 weeks, MCP1 and IL-6
gradually accumulated.
Conclusions: The CXCR4 inhibitor silibinin can ameliorate PAH, possibly through the suppression of the CXCR4/SDF-1
axis, until the point where PAH becomes a severe and irreversible condition. Silibinin results in reduced pulmonary
arterial pressure and delays pulmonary arteriolar occlusion and pulmonary vascular remodeling.
Keywords: Pulmonary arterial hypertension, Silibinin, CXCR4, SDF-1, Stem cell, Smooth muscle cell, Lung
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: kawaguchi.nanako@twmu.ac.jp;
nakanishi.toshio@twmu.ac.jp
1Department of Pediatric Cardiology and Adult Congenital Cardiology, Tokyo
Women’s Medical University, 8-1 Kawada-cho, Shinjuku, Tokyo 162-8666,
Japan
Full list of author information is available at the end of the article
Zhang et al. Respiratory Research           (2019) 20:79 
https://doi.org/10.1186/s12931-019-1041-y
Background
The pathogenesis of pulmonary arterial hypertension
(PAH) is intricate and involves endothelial dysfunction,
chronic inflammation, smooth muscle cell proliferation,
pulmonary arteriolar occlusion, apoptosis resistance, and
pulmonary vascular remodeling. Right ventricular over-
load, right heart failure, and death may result from these
severe pathologies [1–3]. No effective treatment has
been discovered yet.
C-X-C chemokine receptor type 4 (CXCR4) plays a
role in multiple pathways in carcinogenesis [4–6].
CXCR4 is expressed in stem/progenitor cells, includ-
ing endothelial and smooth muscle progenitors [7].
The ligand of CXCR4 is stromal cell derived factor-1
(SDF-1), which is also termed C-X-C chemokine lig-
and 12 (CXCL12). Mesenchymal stem cells (MSCs)
contribute to cancer progression through SDF-1/
CXCR4 signaling [8]. However, cells in remodeled
pulmonary arteries (PAs) of patients with pulmonary
hypertension reportedly share similar characteristics
with cancer cells, such as inflammation, increased
proliferation, and decreased apoptosis [9]. Thus, we
predict there is also an association between CXCR4/
MSCs and the pathogenesis of PAH. CXCR4 and
MSCs may also play a role in the chemotaxis, prolif-
eration, and survival of smooth muscle cells, endothe-
lial cells, or other cell types [10].
We previously reported that CXCR4 and other stem/
progenitor cell markers, such as c-Kit, SCF, CD29, and
CD90, are significantly higher in PAH rats than in nor-
mal rats [11]. Other studies have also reported that
CXCR4 and/or c-Kit positive cells are critical in the de-
velopment of pulmonary hypertension and vascular re-
modeling in rats [12–18]. While the small-molecule
CXCR4 inhibitor AMD3100 (Plerixafor) prevents pul-
monary arterial muscularization in several PAH models
[12, 15–17], efficacious alternative CXCR4 inhibitors for
PAH treatment are scarce.
We investigated the effect of another CXCR4 inhibi-
tor. Silibinin is derived from the seeds of the milk
thistle plant (Silybum marianum (L.)) [19]. Silibinin
has been used in the clinical treatment of liver dis-
eases [20] and it may be potentially useful to treat
cancer [21–25]. Silibinin is a mixture of two flavono-
lignans, namely silybin A (Sil A) and sylybin B (Sil
B), in a ratio approximately 1:1. Recently, using
nematode Aβ amyloidogenesis model, it was discov-
ered that Sil B completely inhibited amyloid β (Aβ)
growth both in vitro and in vivo. On the other hand,
Sil A did not show such an effect [26].
Silibinin and AMD3100 are thought to work in differ-
ent ways [27–30]. We evaluated the ameliorative effect
of silibinin over time using a rat monocrotaline (MCT)
PAH model with chronic hypoxia exposure.
Methods
Animal preparation
MCT (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in 1 N HCl, neutralized with 1 N NaOH, and
diluted with distilled water to 20 mg/mL. A dose of
60 mg/kg (3 mL/kg) body weight was administered to
the rats [31]. All rats had unlimited access to food
and water and were weighed weekly. Silibinin (Sig-
ma-Aldrich) was suspended in 0.5% carboxymethyl
cellulose (CMC) sodium salt water (Wako Pure
Chemical Industries, Ltd., Osaka, Japan).
Male, 7–8-week old Sprague-Dawley rats weighing
180–250 g (Tokyo Experimental Animal Company,
Tokyo, Japan) were randomly assigned to eight groups.
Four of the groups were PAH only groups. In these
groups, the rats were subcutaneously injected with a sin-
gle dose of MCT and maintained in a 10% hypoxic air
chamber (Everest Summit II Altitude Generator) for 1,
2, 3, and 5 weeks. These groups were designated
PAH-1w (n = 8), PAH-2w (n = 8), PAH-3w (n = 4) and
PAH-5w (n = 8), respectively. Every rat in the PAH
groups received CMC water without silibinin orally
every day.
Three of the groups were PAH + silibinin. The rats
were also subcutaneously injected with a single dose of
MCT and maintained in a 10% hypoxic air chamber for
1 week (Sil-1w, n = 8), 2 weeks (Sil-2w, n = 8), and 3
weeks (Sil-3w, n = 4). Silibinin (200 mg/kg) with CMC
water were supplied orally per day. An additional Sil-5w
group is shown in Additional file 1.
Finally, in the control group (n = 8) the rats were sub-
cutaneously injected with a single dose of 0.9% saline
and maintained in a chamber with normal air for 5
weeks.
All animal experiment protocols were approved by the
Institutional Animal Experiment Committee of the
Tokyo Women’s Medical University (AE18–111). All
animal procedures were in accordance with the ethical
standards of the institution and conformed to the guide-
lines from Directive 2010/63/EU of the European Parlia-
ment on the protection of animals used for scientific
purposes or the current NIH guidelines (NIH publica-
tion No. 85–23).
Hemodynamic and functional studies
All rats were anesthetized by isoflurane inhalation
(2.0% mixed with air, at an inhalation rate of approxi-
mately 350 mL/min) at each time point. Heart rate
and respiratory monitoring were used to confirm the
adequacy of anesthesia. A microtube was inserted into
the right ventricle via the right jugular vein to
measure the right ventricular systolic pressure (RVSP).
The catheter was connected to a PowerLab Data
Acquisition system and Lab Chart 7 software
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(ADInstruments, Dunedin, New Zealand) to record
the data. The rats were sacrificed under isoflurane in-
halation by cervical dislocation. Tissues (heart, lungs,
and PAs) were isolated and harvested; the free wall of
the right ventricle (RV) and the left ventricle and
septum (LV + S) were separated and weighed to meas-
ure the Fulton index (weight ratio of RV to LV + S).
Morphometric examinations
Immunohistochemical staining was performed as previ-
ously described [11]. Primary antibodies against
alpha-smooth muscle actin (SMA, 1:1000; Sigma-Aldrich),
proliferating cell nuclear antigen (PCNA, 1:500;
Sigma-Aldrich), CXCR4 (1:1000; Abcam, Cambridge, UK),
and c-Kit (1:100; Santa Cruz Biotechnology, Dallas, TX,
USA) were used.
SMA staining was used to demonstrate smooth muscle
cells in PA walls and to calculate the percent medial wall
thickness (% MT). The external diameter (ED) and MT
were measured in muscularized PAs, whose EDs varied
from 50 to 100 μm, to calculate % MT = (2 ×MT/ED) ×
100 [32]. PCNA staining was used to calculate the vas-
cular occlusion score (VOS) of PAs, which was catego-
rized as Grade 0 (no evidence of neointimal formation),
Grade 1 (< 50% luminal occlusion), or Grade 2 (> 50%
luminal occlusion) [33]. For all evaluations, 15
intra-acinar PAs per section from each rat were ran-
domly selected.
CXCR4 and c-Kit staining were performed to compare
protein expression and the number of stem cells in lung
tissue. Since CXCR4+ cells aggregated, it was impractical
to count individual cells. Hence, only c-Kit+ cells were
counted and then compared between or among the
groups. For each type of staining, we randomly chose 15
microscopic areas per section from each rat.
Reverse transcription-quantitative polymerase chain
reaction (RT-qPCR)
RNA was isolated from the small PA or lung tissue in
the left and right lower lobes of the lung using the
RNeasy Mini Kit (QIAGEN, Hilden, Germany). Comple-
mentary DNA (cDNA) was synthesized using the Prime-
Script™ RT Reagent Kit (Takara Bio, Shiga, Japan). qPCR
was performed using a PikoReal Real-Time PCR System
(Thermo Fisher Scientific, Waltham, MA, USA). Each
sample was analyzed in triplicate. β-actin mRNA expres-
sion was measured for normalization. mRNA expression
was normalized to β-actin expression using the 2-ΔΔCT
equation. Primer sequences are listed in Additional file 1:
Table S1.
Statistical analyses
Quantitative data are expressed as mean ± standard devi-
ation. Statistical analyses performed between two groups
were analyzed by t-test. Comparison of the time-course
was analyzed by one-way analysis of variance (ANOVA)
and Bonferroni’s post hoc test. Comparison of the time
course together with silibinin effect and other factors,
including RVSP and VOS, was analyzed by two-way
ANOVA. SPSS software (SPSS, Inc., Chicago, IL, USA)
was used for all statistical analyses. A p-value < 0.05 was
considered statistically significant.
Results
Animal survival rate
All rats in the control group and 1-, 2-, and 3-week
groups survived and remained active during the experi-
ment. In contrast, three rats in the PAH-5w group died
after 4 weeks of the experimental treatment.
Effect of silibinin with time in the PAH models
We used several doses of silibinin (0, 50, 100, 200 mg/
kg), and found that it is effective in a dose-dependent
manner (data not shown). Therefore, a dosage of 200
mg/kg silibinin was selected for subsequent experiments.
Silibinin significantly decreased RVSP (p < 0.01) and
the Fulton index (p < 0.05) after the 1-week treatment
(Fig. 1a) and 2-week treatment (both p < 0.05, Fig.
1b). However, no significant difference was observed
between the PAH-3w and Sil-3w groups in terms of
hemodynamic levels (Fig. 1c). To further investigate
the effectiveness of silibinin, staining was carried for
SMA (Fig. 1d) and PCNA (Fig. 1e), and % MT as well
as VOS were calculated (Fig. 1f-h). A significant dif-
ference was observed only for the 2-week treatment
(p < 0.05, Fig. 1g).
RT-qPCR revealed that 1 week treatment of silibinin
did not downregulate the expression of stem
(See figure on previous page.)
Fig. 1 Hemodynamic studies and immunohistochemical evaluation of PAH models with and without silibinin. a Silibinin decreased RVSP
and Fulton index in the Sil-1w group compared to the PAH-1w group. b Silibinin also decreased RVSP and Fulton index in the Sil-2w
group compared to the PAH-2w. c Silibinin did not decrease RVSP and Fulton index during the 3-week experiment. d SMA staining
revealed thinner media smooth muscle layer in the Sil-2w group compared to that in the PAH-2w group, but this was no longer found
after 1 or 3 weeks. e PCNA staining revealed less proliferation in PAs in the Sil-2w group compared to PAH-2w, but no change was
observed when compared to the 1- and 3-week treatment periods. f-h % MT and VOS were calculated at 1 week (f), 2 weeks (g), and 3
weeks (h) of treatment. Significant differences were found at the 2-week time point only (g); *p < 0.05 and **p < 0.01. Treatment groups
consisted of eight rats each in the PAH-1w, PAH-2w, Sil-1w, and Sil-2w groups and four rats each in the PAH-3w and Sil-3w groups
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cell-related (CXCR4/SDF-1/c-Kit/SCF) and inflamma-
tory (MCP1/IL-6/TNFα) markers in PAs (Fig. 2a).
After 2 weeks, silibinin downregulated the expression
of CXCR4, SDF-1, and TNFα in PAs, and a signifi-
cant difference was observed between the PAH-2w
and Sil-2w groups (p < 0.01). However, a significant
difference was not observed in the expression of
c-Kit, SCF, MCP1, and IL-6 in PAs between the
PAH-2w and Sil-2w groups (Fig. 2b). After 3 weeks,
silibinin failed to downregulate the expression of stem
cell-related and inflammatory markers in PAs (Fig.
2c). To determine whether the strong expression of
stem cells and inflammatory markers was specific to
PAs, RT-qPCR was also done on lung tissue after 2
weeks of silibinin treatment. In contrast to PAs, silibi-
nin did not downregulate the expression of stem cells
and inflammatory markers in lung tissue (Fig. 2d).
Immunohistochemical staining was performed to fur-
ther investigate the efficacy of silibinin. CXCR4+ (Fig. 3a)
and c-Kit+ cells (Fig. 3b) in close proximity to PAs were
more strongly expressed than in other parts of the lung
tissue. No significant difference in the number of c-Kit+
cells were observed at any time point (Fig. 3c).
Time course results with PAH rats
We investigated stem cell and inflammatory marker ex-
pression during a time course study of the progression
of PAH. Over time, gradual increases of RVSP (Fig. 4a),
Fulton index (Fig. 4b), % MT (Fig. 4c), and VOS (Fig.
4d) were observed.
Rats in the PAH-2w group exhibited significantly
higher CXCR4 gene expression than the control (p <
0.001), PAH-1w (p < 0.001), PAH-3w (p < 0.01), and
PAH-5w (p < 0.01) groups (Fig. 5a). Rats in the PAH-1w
group exhibited significantly less SDF-1 mRNA expres-
sion levels than the control group (p < 0.01). After 1
week of the PAH condition, SDF-1 mRNA expression
started to increase. SDF-1 gene expression was signifi-
cantly higher in the PAH-3w group than in the control
(p < 0.001), PAH-1w (p < 0.001), PAH-2w (p < 0.001), and
PAH-5w (p < 0.001) groups (Fig. 5b). Results of the gene
expression analysis of c-Kit and SCF were similar to
those of SDF-1 (Fig. 5c, d). Additionally, gene expression
of the inflammatory marker TNFα were similar to
CXCR4 (Fig. 5e). Furthermore, a gradual increase in
gene expression was found for two other inflammatory
markers, MCP1 (Fig. 5f ) and IL-6 (Fig. 5g). All stem cell
markers examined showed decreased levels in the
PAH-1w group compared to the normal group, but
started to increase thereafter.
During the time course study, the number of c-Kit+
cells detected by immunohistochemical staining was
greater in the PAH-2w group than in the control (p <
0.05) and PAH-1w groups (p < 0.05). Additionally, c-Kit+
cells in the PAH-3w group were significantly increased
compared to the control (p < 0.001), PAH-1w (p < 0.001),
and PAH-2w (p < 0.05) groups. However, their expres-
sion started to decrease thereafter (Fig. 5h). The results
of two-way ANOVA are shown in Additional file 1.
Discussion
There are four main findings of the present study.
Firstly, a 1-week silibinin treatment in the PAH models
reduced RVSP and Fulton index. A 2-week treatment re-
duced RVSP, Fulton index, % MT, VOS, and downregu-
lated CXCR4, SDF-1 and TNFα gene expression in PAs.
In contrast to these results, a 3-week treatment failed to
ameliorate PAH symptoms. These results suggest that
silibinin can ameliorate PAH and reduce pulmonary ar-
terial pressure in the early phases of its development,
but is an ineffective treatment in late stages of the dis-
ease. Furthermore, silibinin may delay pulmonary arteri-
olar occlusion and pulmonary vascular remodeling
through the suppression of the CXCR4/SDF-1 axis.
Secondly, after the 2-week silibinin treatment, stem
cell-related and inflammatory markers were downregu-
lated in PAs, but not in lung tissue. Thirdly, in the earli-
est period at which PAH development was measured
(1-week MCT + hypoxia), the CXCR4 mRNA expression
and other stem cell-related markers were lower than in
normal rats. Fourthly, during this time course study,
RVSP, Fulton index, % MT, and VOS continued to in-
crease over time, but gene expression patterns were dis-
tinct, as CXCR4 and TNFα started to decline after 2
weeks of PAH. However, c-Kit, SCF, and SDF-1 were still
accumulating after 2 weeks and started to decline after 3
weeks of PAH development. In contrast, the
(See figure on previous page.)
Fig. 2 Gene expression levels of stem cell-related markers and inflammatory markers. Total RNA from PAs was used for reverse
transcription (RT), and quantitative polymerase chain reaction (qPCR) was performed. The message was normalized to β-actin using the 2-
ΔΔCT eq. a Silibinin did not downregulate the expression of stem cell-related and inflammatory markers in PAs after a 1-week treatment. b
Silibinin significantly downregulated the expression of CXCR4, SDF-1 as well as TNFα in PAs after a 2-week treatment. c Silibinin did not
downregulate the expression of stem cell-related and inflammatory markers in PAs after a 3-week treatment. d Silibinin did not
downregulate the expression of stem cell-related and inflammatory markers in lung tissue after a 2-week treatment; **p < 0.01. Treatment
groups consisted of eight rats each in the PAH-1w, PAH-2w, Sil-1w, and Sil-2w groups and four rats each in the PAH-3w and
Sil-3w groups
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inflammatory markers MCP1 and IL-6 accumulated
throughout the 5-week time period.
One week of silibinin treatment could ameliorate
RVSP and Fulton index, however, no significant differ-
ence in gene expression was observed between the
PAH-1w and Sil-1w groups. Simultaneously, in the time
course study, we demonstrated that CXCR4 mRNA ex-
pression and other stem cell-related markers were lower
than in normal rats. A plausible explanation for this
finding is that at the onset of the severe stage, models
need time to adapt. Thus, mRNA expression of most
stem cells decreased compared with their normal healthy
counterparts.
Two weeks of silibinin treatment could ameliorate
PAH, as indicated by the downregulation of RVSP, Ful-
ton index, % MT, VOS, and the CXCR4, SDF-1, and
TNFα gene expression results. However, these differ-
ences were not observed in c-Kit, SCF, MCP1, and IL-6
gene expression levels, or c-Kit protein expression level.
One possible reason is that silibinin downregulated the
expression of CXCR4 and its SDF-1 ligand, and some of
the inflammatory markers, but failed to have an effect
on the other stem cell markers or inflammatory markers
tested. This indicates silibinin may be different from an-
other CXCR4 inhibitor, AMD3100.
Previously, AMD3100 treatment was shown to attenu-
ate pulmonary angiogenesis by reducing the number of
c-Kit+ cells in rat lungs [34], and reduce the number of
proliferating c-Kit+ SMA+ cells in PAH rats [12]. CXCR4
was shown to autologously regulate its expression from
the PTEN experiment [35], suggesting silibinin can func-
tion as a CXCR4 antagonist. CXCR4 has a large ligand
binding cavity, and silibinin binds to transmembrane
TM2 (Asp97), TM5 (Gln200), TM7 (Glu288), and EL2
(Cys186 and Asp187). However, AMD3100 binds to
TM2 (Asp97), TM3 (His113, Tyr116, Thr117, and
Leu120), TM4 (Asp171), TM5 (His203), TM6 (Tyr255),
TM7 (Ser285 and Glu288) and EL2 (Asp187 and
Arg188) [30]. Thus, we speculate that silibinin and
AMD3100 are different CXCR4 inhibitors, with different
structures and mechanisms of binding, leading to differ-
ent efficacies in PAH treatment. In our experiments, sili-
binin may have ameliorated PAH only by suppressing
the CXCR4/SDF-1 axis, independent of c-Kit. This
Fig. 3 Immunohistochemical evaluation of CXCR4 and c-Kit around
PAs. a More CXCR4+ cells after 2 weeks of treatment were observed
compared to 1 and 3 weeks. b c-Kit+ cell numbers after the 3-week
treatment was greater than those observed after the 1- and 2-week
treatments. c There was no significant difference in c-Kit+ cell
numbers between the PAH groups and silibinin groups at any time
point. Treatment groups consisted of eight rats each in the PAH-1w,
PAH-2w, Sil-1w, and Sil-2w groups and four rats each in the PAH-3w
and Sil-3w groups
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contrasts with results previously found in AMD3100 ex-
periments [12].
Silibinin treatment reduced pulmonary arterial pres-
sure and pulmonary arteriolar occlusion, and slowed
pulmonary vascular remodeling. Additionally, it is inter-
esting that after a 2-week treatment, silibinin downregu-
lated the gene expression of stem cell and inflammatory
markers in PAs, but not in lung tissue. We also observed
higher numbers of CXCR4+ and c-Kit+ cells around the
PAs than in other parts of the lung tissue by immuno-
histochemical staining. From these results, we propose
that the expression of CXCR4 and c-Kit may be greater
in and around PAs instead of other parts of the lung tis-
sue. Therefore, silibinin would be especially effective
around PAs.
Three weeks of silibinin treatment could not amelior-
ate PAH at any level tested. Being housed under hypoxic
conditions for a long period, PAH may have already be-
come an irreversible condition. Therefore, the condition
of the animals could not be ameliorated by CXCR4 in-
hibitors. Compared to rats in the PAH-3w group, rats in
the PAH-5w group had poorer results in terms of RVSP,
Fulton index, % MT, and VOS measurements because of
the presence of more severe PAH. Intraperitoneal
injection of silibinin did not produce a difference (Add-
itional file 1).
In the time course study, we successfully established a
PAH model using a combination of MCT and chronic
hypoxia, which may be more similar to clinical PAH
than a single treatment [36]. RVSP, Fulton index, % MT,
and VOS gradually increased over time, in agreement
with other PAH models that gradually become more
severe.
CXCR4 is expressed in stem/progenitor cells, in-
cluding endothelial and smooth muscle progenitors
[7]. c-Kit is a common marker of progenitor and stem
cells, including the lung stem cells, which can re-
populate airways and vessels [37], and vascular endo-
thelial stem cells, which can generate functional blood
vessels [38]. SDF-1 is highly expressed in the bone
marrow stromal cells, but it is also widely expressed
throughout organs, such as the brain, heart, liver, and
lung [39]. The results of our time course study indi-
cated that even though PAH treatment became pro-
gressively more severe over time, gene expression
changes were variable. For example, CXCR4 and
TNFα started to decline after 2 weeks of the PAH
condition, SDF-1, c-Kit, and SCF started to decline
Fig. 4 Time course of hemodynamic and immunohistochemistry of PAH models. a, b Significant differences were observed between each group,
except between the PAH-2w and PAH-3w groups for RVSP (a) and Fulton index (b). c and d % MT (c) and VOS (d) increased over time within 5
weeks of PAH development; *p < 0.05, **p < 0.01, and ***p < 0.001. Treatment groups consisted of eight rats each in the control, PAH-1w, and
PAH-2w groups, four rats in the PAH-3w group, and five rats in the PAH-5w group
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after 3 weeks, while MCP1 and IL-6 gradually accu-
mulated over 5 weeks. One possible explanation is
that CXCR4+ progenitor and stem cells differentiate
into endothelial or smooth muscle cells at approxi-
mately 2 weeks in our PAH model. However, SDF-1+,
c-Kit+, and SCF+ progenitor and stem cells differenti-
ated into lung, vascular endothelial, or other cells
around the third week of PAH development in our
model. The inflammatory markers MCP1 and IL-6
gradually accumulated over time, which indicated
more severe inflammation over time. However, in
contrast to MCP1 and IL-6, TNFα expression was
distinct. One possible reason is that at approximately
2 weeks, normal cell apoptosis peaked. TNFα expres-
sion reflected the apoptosis of these normal cells.
Although CXCR4+ and c-Kit+ cells were distributed in
whole lung tissue, a greater number of positive cells
were observed around the PAs than in other parts of the
lung tissue, as previously described. We counted the
number of c-Kit+ cells after 3 weeks of the PAH condi-
tion, and c-Kit expression started to decline. This sug-
gested c-Kit expression correlates with its gene
expression in PAs. In contrast, CXCR4+ cells aggregated,
leading to difficulty counting individual cells. This was
possibly because CXCR4 is widely expressed on endo-
thelial cells, neutrophils, monocytes, hematopoietic, and
tissue-committed stem cells [40], all of which may exist
in lung tissue or PAs during PAH development.
The present study has some limitations. Firstly, rat
models are less complex than clinical patients even
though we established our model by combining MCT
and chronic hypoxia. Secondly, we studied silibinin only,
which may have a mechanism that is distinct from
AMD3100 in PAH treatment. The role of other CXCR4
inhibitors to prevent PAH remains unclear. Thirdly, it is
not clear which silibinin component, Sil A or Sil B, is ef-
fective for PAH. Silibinin is difficlut to dissolve in water.
To improve its efficacy in vivo, chemically modified sili-
binin has been developed [41, 42]. The modified silibinin
may be more effective than original sillibinin for PAH
patients. Lastly, there is a possibility that higher dose of
silibinin may be more efficacious. However, side effects
of silibinin in PAH patients are still unknown. Therefore,
further studies to compare efficacy and side effects of
different CXCR4 inhibitors in PAH treatment are mean-
ingful and necessary, and may provide more options for
PAH clinical treatment.
Conclusions
Our experimental results suggest that if the CXCR4 in-
hibitor silibinin is used to ameliorate PAH prior to PAH
becoming a severe and irreversible condition, the
CXCR4/SDF-1 axis may be suppressed, leading to a re-
duction in pulmonary arterial pressure and pulmonary
arteriolar occlusion. Additionally, a deceleration of pul-
monary vascular remodeling may occur. This study pro-
vided basic evidence supporting the use of the CXCR4
inhibitor silibinin for the treatment of PAH. Hence, sili-
binin may be another potential treatment for PAH and
may provide a new option for some PAH patients.
Additional file
Additional file 1: Table S1. Primers used for RT-qPCR. Table S2. The p
value of two-way ANOVA analysis. Figure S1. Measurement of RVSP in
different groups. Figure S2. The results of two-way ANOVA analysis. Figure
S3. Hemodynamic studies, immunohistochemical evaluation, and gene
expression of PAH-5w and Sil-5w groups. (ZIP 6575 kb)
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Fig. 5 Expression of stem cell-related and inflammatory markers during the time course of PAH development. a CXCR4 gene expression in the
PAH-2w group was significantly higher than in the control, PAH-1w, PAH-3w, and PAH-5w groups. After 2 weeks of PAH development, CXCR4
expression started to decrease. b SDF-1 gene expression level in the PAH-1w group was significantly less than the control group. After 1 week of
PAH development, SDF-1 expression started to increase, and was significantly higher in the PAH-3w group than in the control, PAH-1w, PAH-2w,
and PAH-5w groups. After 3 weeks of PAH development, SDF-1 expression started to decrease. c and d c-Kit (c) and SCF (d) gene expressions
exhibited the same tendency and had results similar to SDF-1. e The change in the gene expression level of inflammatory marker, TNFα, was
similar to that of CXCR4. f and g The gene expressions of inflammatory markers MCP1 (f) and IL-6 (g) gradually increased over time. h
Immunohistochemical staining of c-Kit was compared in this time course study. c-Kit+ cell number in the PAH-2w group was significantly greater
than in the control and PAH-1w groups. c-Kit+ cell number in the PAH-3w group was also significantly greater than in the control, PAH-1w, and
PAH-2w groups. After 3 weeks of PAH development, c-Kit expression started to decrease; *p < 0.05, **p < 0.01, and ***p < 0.001. Treatment groups
consisted of eight rats each in the control, PAH-1w, and PAH-2w groups, four rats in the PAH-3w group, and five rats in the PAH-5w group
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